ASCO 2023 | How can we best sequence novel treatments in urothelial cancer?

Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, comments on the changing field of urothelial cancer, including novel therapies such as enfortumab vedotin and erdafitinib, which have been assessed in the EV-103 trial (NCT03288545) and THOR (NCT03390504) trials, as well as sacituzumab govitecan. Treatment can depend on the FGFR status of patients, where erdafitinib has shown benefit in patients with FGFR alterations. Adverse events can additionally influence which drug a patient will receive. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.